MADISON, Wis.--(EON: Enhanced Online News)--The new CHOgro™ Expression System by Mirus Bio addresses the low
transient gene expression levels in early stage drug development by
providing researchers a system that achieves high titers in suspension
CHO cells allowing them to quickly obtain sufficient quantities of
relevant candidate proteins.

“By providing a system that works
with relevant CHO cells from the beginning to the end of the workflow,
scientists can now have confidence in their experiments and focus on
what really matters, the drug targets.”

The CHOgro™ Expression System is a robust and simple CHO transient
protein expression system enabled by critical media attributes such as
high density cell growth, quick adaptation and minimization of cell
clumping post-transfection. By optimizing the components of the system
antibody titers increased 2-10 fold over existing technologies with
higher amounts of antibody secreted per cell. Components of the system
include: the CHOgro™ Expression Medium, TransIT-PRO®
Transfection Reagent, CHOgro™ Complex Formation Solution, Poloxamer 188
and L-glutamine. Six different representative antibody constructs were
tested using this system and notably even CHO cells maintained in other
commercially available media formulation (e.g. FreeStyle™ CHO Expression
Medium) can be easily adapted with a full media exchange to the CHOgro™
Expression Medium 24-hours prior to transfection and yield multi-fold
increases in transient expression levels.

“We are confident this new system will address the needs of researchers
in early stage drug development,” said Scott Hayes, Ph.D., Vice
President of Scientific Operations. “By providing a system that works
with relevant CHO cells from the beginning to the end of the workflow,
scientists can now have confidence in their experiments and focus on
what really matters, the drug targets.”

“The entire system has advantages over other available approaches. The
medium and transfection reagent work seamlessly and produce superior
results when swapped with components in other commercial systems,” Hayes
added. “Not only will researchers see an increase in titers with
competitive systems including linear 25kDa PEI, they will also be able
to appreciate significant cost savings.”

With the introduction of this new system, interested researchers can
visit www.mirusbio.com/chogro
for comprehensive information about the CHOgro™ Expression System and
register to qualify for a trial kit.

CELEBRATING 20 YEARS: PROVIDING GENE DELIVERY EXPERTISE SINCE 1995

Mirus Bio pioneered scientific breakthroughs in non-viral gene delivery.
These advancements established our products as industry leading
transfection reagents. As we continue to expand our expertise in nucleic
acid delivery research, we look to enhance output in biotherapeutic
protein production, lentivirus production and genome editing.